Tech Company Financing Transactions
Celea Therapeutics Funding Round
Celea Therapeutics closed a $180 million investment round on 7/2/2026. Backers included Leaps by Bayer, PureTech Ventures and RA Capital Management.
Transaction Overview
Company Name
Announced On
7/2/2026
Transaction Type
Venture Equity
Amount
$180,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds for the planned early Q3 2026 initiation of the Phase 3 SURPASS-IPF trial of deupirfenidone (LYT-100), an investigational next-generation antifibrotic with the potential to serve as a new standard of care for people living with idiopathic pulmonary fibrosis (IPF).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6 Tide Street 400
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Undisclosed
Website
Email Address
Overview
Celea Therapeutics is dedicated to advancing transformative treatments for people with serious respiratory diseases. Drawn from the Latin word for "sky," our name reflects our mission: to rise above the status quo and deliver therapies that change lives. Our lead program, deupirfenidone (LYT-100), is advancing into Phase 3 development with the potential to set a new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sven Dethlefs
Browse more venture capital transactions:
Prev: 7/2/2026: Air Energy venture capital transaction
Next: 7/2/2026: Qolab venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs